PMID- 31291263
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 7
DP  - 2019
TI  - Risk factors for cytomegalovirus infection in patients with antineutrophil 
      cytoplasmic antibody-associated vasculitis.
PG  - e0218705
LID - 10.1371/journal.pone.0218705 [doi]
LID - e0218705
AB  - AIMS: Cytomegalovirus (CMV) infection under immunosuppression sometimes causes 
      death. This study aimed to elucidate risk factors for CMV infection in patients 
      with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: 
      Patients with AAV who underwent remission induction treatment at Okayama 
      University Hospital between 2006 and 2016 were retrospectively analyzed. The 
      primary outcome was the development of CMV infection within 3 months. RESULTS: Of 
      the 111 patients, 13 (11.7%) patients developed CMV infection. Patients with CMV 
      infection were older (p = 0.030) and had a higher body mass index (p = 0.029) in 
      comparison to those without CMV infection. A higher proportion had a severe form 
      (p = 0.001) and granulomatosis with polyangiitis (GPA) (p = 0.001), as well as a 
      higher Birmingham Vasculitis Activity Score (p = 0.018) and C-reactive protein (p 
      = 0.018) levels at baseline. Using logistic regression analysis, severe form and 
      GPA were independent risk factors (odds ratio [OR] = 9.68, 95% confidence 
      interval [CI] = 1.92-60.23, and OR = 7.46, 95% CI = 1.46-47.60, respectively). In 
      addition, patients with CMV infection were more likely than those without 
      infection to be glucocorticoid-related diabetes mellitus (p = 0.025). CONCLUSION: 
      Our study highlights disease severity and subgroups of AAV as risk factors for 
      CMV infection.
FAU - Morishita, Michiko
AU  - Morishita M
AUID- ORCID: 0000-0001-8939-4816
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Sada, Ken-Ei
AU  - Sada KE
AUID- ORCID: 0000-0003-1020-0818
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Matsumoto, Yoshinori
AU  - Matsumoto Y
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Hayashi, Keigo
AU  - Hayashi K
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Asano, Yosuke
AU  - Asano Y
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Hiramatsu Asano, Sumie
AU  - Hiramatsu Asano S
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Ohashi, Keiji
AU  - Ohashi K
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Miyawaki, Yoshia
AU  - Miyawaki Y
AUID- ORCID: 0000-0002-6981-3443
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Katsuyama, Eri
AU  - Katsuyama E
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Watanabe, Haruki
AU  - Watanabe H
AUID- ORCID: 0000-0001-7837-086X
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Kawabata, Tomoko
AU  - Kawabata T
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
FAU - Wada, Jun
AU  - Wada J
AD  - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama 
      University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
      Okayama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190710
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Immunosuppressive Agents)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Aged
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/drug 
      therapy/*immunology/pathology
MH  - Antibodies, Antineutrophil Cytoplasmic/*blood
MH  - Body Mass Index
MH  - C-Reactive Protein/metabolism
MH  - Cytomegalovirus/*immunology/isolation & purification/pathogenicity
MH  - Cytomegalovirus Infections/diagnosis/etiology/*immunology/virology
MH  - Female
MH  - Granulomatosis with Polyangiitis/diagnosis/drug therapy/*immunology/pathology
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/adverse effects
MH  - Japan
MH  - Logistic Models
MH  - Male
MH  - Methylprednisolone/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Opportunistic Infections/diagnosis/etiology/*immunology/virology
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
PMC - PMC6619987
COIS- The authors declare the following interests: JW received speaking honoraria from 
      Astellas, Boehringer Ingelheim, Daiichi Novartis, Sankyo, and Tanabe Mitsubishi, 
      and grant support from Astellas, Bayer, Baxter, Chugai, Daiichi Sankyo, Kissei, 
      Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Ono, Otsuka, Pfizer, Teijin, 
      Torii, and Takeda. KS has received lecture fees from Chugai. All other authors 
      declare that they have no competing interests. This does not alter our adherence 
      to PLOS ONE policies on sharing data and materials.
EDAT- 2019/07/11 06:00
MHDA- 2020/02/23 06:00
PMCR- 2019/07/10
CRDT- 2019/07/11 06:00
PHST- 2018/07/11 00:00 [received]
PHST- 2019/06/07 00:00 [accepted]
PHST- 2019/07/11 06:00 [entrez]
PHST- 2019/07/11 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/07/10 00:00 [pmc-release]
AID - PONE-D-18-20504 [pii]
AID - 10.1371/journal.pone.0218705 [doi]
PST - epublish
SO  - PLoS One. 2019 Jul 10;14(7):e0218705. doi: 10.1371/journal.pone.0218705. 
      eCollection 2019.